University of Calgary

PBRM1 but not BAP1 deficiency is a frequent feature of multifocal non-cystic low-grade clear cell renal cell carcinoma (2019) Agaimy A, Trpkov K, Gao Y, Hartmann A, Hes O Conference contribution To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps (2019) Boeltz S, Amini P, Anders HJ, Andrade F, Bilyy R, Chatfield S, Cichon I, et al. Journal article, Review article The Immune Landscape of Cancer. (2019) Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO, Porta-Pardo E, et al. Journal article, Erratum The ASKAP EMU early Science project: Radio continuum survey of the Small Magellanic Cloud (2019) Joseph TD, Filipović MD, Crawford EJ, Bojičić I, Alexander EL, Wong GF, Andernach H, et al. Journal article, Review article Gout, hyperuricaemia and crystal-associated disease network (G-CAN) consensus statement regarding labels and definitions of disease states of gout (2019) Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, et al. Journal article Anelastic reorganisation of fibre-reinforced biological tissues (2019) Di Stefano S, Carfagna M, Knodel M, Hashlamoun K, Federico S, Grillo A Journal article Gata6+ Pericardial Cavity Macrophages Relocate to the Injured Heart and Prevent Cardiac Fibrosis (2019) Deniset JF, Belke D, Lee WY, Jorch SK, Deppermann C, Hassanabad AF, Turnbull JD, et al. Journal article Opposite dynamics of GABA and glutamate levels in the occipital cortex during visual processing (2018) Kurcyus K, Annac E, Hanning NM, Harris AD, Oeltzschner G, Edden R, Riedl V Journal article Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis (2018) Natanzon Y, Kobel M, Winham SJ, Armasu SM, Mccauley BM, Vierkant RA, Cunningham JM, et al. Conference contribution Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution